Browse drugs

…s In 06/2025, the patient began treatment with tremelimumab and durvalumab. Three weeks after the first cycle he developped cough and desa…

…ducted, no agents have received approval, with the exception of valrubicin, largely attributed to factors such as the varied prior BCG exp…

…im T-Y, Tai WMD, Kang Y-K, Lau G, et al. Safety and efficacy of durvalumab plus bevacizumab in unresectable hepatocellular carcinoma: resu…

…Background Combination immunotherapies such as atezolizumab plus bevacizumab (Atez/Bev) and durvalumab plus tremelimumab (D…

…Results In 2023 and 2024 we used seven immunotherapeutic drugs: pembrolizumab (230 patients), durvalumab (45 patients), atezolizumab (45 pati…

…se of a patient with hepatocellular carcinoma on durvalumab and tremelimumab who developed severe ICI pneumonitis and acute hypoxic respirat…

…ith filters for RCTs. We restricted our analysis to ipilimumab, nivolumab, pembrolizumab, atezolizumab, avelumab, durvalumab, cemiplimab …

…rable (figure 2). Consistent with the tumor-activated design of vilastobart, treatment was generally well-tolerated: overall (n=44), 11 pat…

…nicalTrials.gov between 2014 and 2024 evaluating approved ICIs (nivolumab, pembrolizumab, atezolizumab, durvalumab, avelumab, ipilimumab,…

…otherapy, 563 (87.4%) received atezolizumab; 61 (9.5%) received durvalumab. We found that the median OS was 9 months vs 7.2 months (p <0.0…

…nically approved anti-CTLA-4 antibodies, such as ipilimumab and tremelimumab, target Tregs to exert anti-tumor effects. However, their use r…

… the cornerstone of treatment for advanced-stage disease. While lenvatinib has been a widely used first-line agent, the advent of immunoth…